% | $
Quotes you view appear here for quick access.

Prima Biomed Ltd. Message Board

  • p_tradr p_tradr Oct 19, 2012 12:12 AM Flag

    Prima BioMed Announces Changes to the Board and Senior Management

    SYDNEY, AUSTRALIA--(Marketwire -05/23/12)- Prima BioMed Ltd (PRR.AX) (PBMD) ("Prima" or the "Company") advises of the following changes to senior management and the board of directors.

    The Company's Chief Executive Officer, Martin Rogers, will step down effective 31 August 2012. Mr. Rogers will remain on Prima's board as a non-executive director from 1 September 2012.

    Matthew Lehman, the Company's Chief Operating Officer, will assume the CEO role effective 1 September 2012. Mr. Lehman will join the Prima board of directors effective immediately. Mr. Lehman will be the Acting CEO during the period of Mr. Rogers' nuptial leave until the end of July 2012.

    These changes are intended to facilitate CVac's continued clinical and regulatory development, and position Prima for the Company's next stage of growth.

    Prima Chairman Lucy Turnbull AO said: "On behalf of the Company, we would like to thank Martin Rogers for his tireless work in transforming Prima over the past 4 1/2 years. Under his leadership, Martin consolidated Prima's research activities to focus on development of CVac, he brought together a strong management team and board of directors, and he has overseen the globalization of Prima's development activities with key operations in the USA and Germany. As Martin transitions out of active management, he leaves the Company in a strong financial position with significant opportunity for growth. On behalf of everyone at Prima, we thank Martin for his service and wish him well in his future endeavors."

    Mr. Rogers said: "It has been an honor to serve patients, the medical community, and our shareholders over the past 4 1/2 years. I have every confidence that the Prima team is in an excellent position to capitalize on the success the Company has achieved to date, in both the clinical programs for CVac™ and at the corporate level. Prima has a world class management team and it has been a privilege to work with such a talented group. I would like to acknowledge the outstanding support of the board and all the Prima team during my tenure as CEO."

    Ms. Turnbull continued: "We are confident that Matthew Lehman's extensive experience in product development and clinical trial execution will serve Prima well in the next stages of the Company's growth. After successfully leading Prima's operations and clinical development for over 2 years, he is a natural choice for this role."

0.888+0.008(+0.91%)Jul 26 4:00 PMEDT